Transcription of FRCP Protocol Manual - VFS International
{{id}} {{{paragraph}}}
Document Author: Head of SHEQ Document Reviewer: Head of SHEQ PAGE DOCUMENT NO. Implemented Date REVISION EFFECTIVE DATE PR-CRC-SHEQ-FRCP 1 - 10 September 2012 2 December 2015 Page 1 of 43 THIS DOCUMENT IS THE PROPERTY OF SAMANCOR CHROME AND IS CONFIDENTIAL. IT MAY NOT BE COPIED OR DIVULGED TO 3RD PARTIES WITHOUT PERMISSION - THIS DOCUMENT IS NOT CONTROLLED IF PRINTED . Title PURPOSE To govern and reduce risk associated with activities related to the Samancor Chrome Fatal Risk Protocols BRIEF DESCRIPTION OF CHANGE All current Samancor Chrome FRCP s incorporated into a combined Manual . Revision 2 Changes added to Annexure 1 page 43 APPROVAL SIGNATURES RECORD REVIEWER ROLE NAME SIGNATURE DATE Document Owner Samancor Chrome, Head of SHEQ, on behalf of the SHEQ Council Hard Copy Signed Dec 2015 Reviewer 1 General Manager, FMT Hard Copy Signed Dec 2015 Reviewer 2 General Manager, MFC Hard Copy Signed Dec 2015 Reviewer 3 General Manager, TFC Hard Copy Signed Dec 2015 Reviewer 4 General Manager, ECM Hard Copy Signed Dec 2015 Reviewer 5 General Manager, WCM Hard Copy Signed Dec 2015 Reviewer 6 Head Of SHEQ Hard Copy Signed Dec 2015 Reviewer
Document Author: Head of SHEQ Document Reviewer: Head of SHEQ PAGE DOCUMENT NO. Implemented Date REVISION EFFECTIVE DATE PR-CRC-SHEQ-FRCP 1 - 10 September 2012 2 December 2015 Page 1 of 43 “THIS DOCUMENT IS THE PROPERTY OF SAMANCOR CHROME AND IS CONFIDENTIAL.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
FIBROSCAN PROGRAM Dr. Magdy Elkhashab, FIBROSCAN PROGRAM Dr.Magdy Elkhashab, FRCP, Taking Killer Corporate Representative Depositions, Taking Killer Corporate Representative Depositions under FRCP, FRCP 45 Third-Party Subpoenas: Using or, Acute Kidney Injury, Chapter 6 The Civil Litigation Process, Benzodiazepine